ASH 2023 | MDM2 inhibitors in myelofibrosis treatment: the addition of navtemadlin to ruxolitinib
John Mascarenhas, MD, Icahn School of Medicine at Mount Sinai, New York, NY, discusses the emerging use of MDM2 inhibitors for treating myelofibrosis (MF). The MDM2 inhibitor navtemadlin elicits some gastrointestinal toxicity when administered as monotherapy; however, when combined with the JAK inhibitor ruxolitinib, this toxicity is reduced, and the combination is well tolerated and efficacious. Dr Mascarenhas hopes this agent will provide a salvage therapy option for patients with sub-optimal responses to ruxolitinib. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Membership on an entity’s Board of Directors or advisory committees: Bristol Myers Squibb, Celgene, Constellation Pharmaceuticals/MorphoSys, CTI BioPharma, Galecto, Geron, GSK, Incyte Corporation, Karyopharm Therapeutics, Novartis, PharmaEssentia, Prelude Therapeutics, Pfizer, Merck, Roche, AbbVie, Kartos; Research Funding: AbbVie, Bristol Myers Squibb, Celgene, Constellation Pharmac, CTI BioPharma, Geron, Incyte Corporation, Novartis, Janssen, Kartos Therapeutics, Merck, PharmaEssentia, Roche; Consultancy: Incyte, Novartis, Roche, Geron, GSK, Celgene/BMS, Kartos, AbbVie, Karyopharm, PharmaEssentia, Galecto, Imago, Sierra Oncology, Pfizer, MorphoSys, CTI Bio, AbbVie, Merck; Honoraria: GSK.
